The recently announced trade deal between the United States and the European Union, which includes a 15% tariff on European goods, has drawn both praise and criticism. Proponents argue that it could avoid a tariff war and facilitate significant energy purchases from the US, while opponents claim that the deal reflects European capitulation and deepens dependence on fossil fuels. European leaders, including Macron, express dissatisfaction with the negotiations, viewing them as a capitulation to Trump. Concerns are also voiced regarding the potential impact of the new tariffs on drug prices, particularly for medications like Ozempic and Wegovy. As the EU prepares to meet US tariff commitments, the broader implications for European competitiveness and energy policy remain hotly debated.